1.Infantile Hemangioendothelioma of the Liver: Brief case report.
Hyang Jeong JO ; Ki Jung YUN ; Jae Kyu LEE ; Ji Shin LEE ; Hyung Bae MOON
Korean Journal of Pathology 1997;31(6):586-588
Infantile hemangioendothelioma of the liver is a common vascular tumor in infancy. The tumor is usually multinodular or diffuse and classified into two types. We present a case of infantile hemangioendothelioma of the liver, which predominantly consists of type 2. A 4-month-old female was admitted for an evaulation of an abdominal distension. A CT scan of the liver showed a multinodular mass. The right lobectomy was done. Grossly, the mass consisted of round nodules ranging from 2cm to 5cm in diameter. Microscopically, the tumor revealed proliferation of small vascular channels lined by endothelial cells. Bizarre cells and mitotic cells were frequently noted. Vesicular nuclei and multilayering of the endothelial cells were also noted.
Endothelial Cells
;
Female
;
Hemangioendothelioma*
;
Humans
;
Infant
;
Liver*
;
Tomography, X-Ray Computed
2.Intraperitoneal Vancomycin Induced Chemical Peritonitis in CAPD Patients.
Jun Bum PARK ; Kyu Hyang JO ; Hang Jae JUNG ; Young Jin KIM ; Joon Young DO ; Kyoung Woo YOON
Korean Journal of Nephrology 1999;18(5):741-746
BACKGROUND: Intraperitoneal(IP) vancomycin has been widely used for the treatment of peritonitis or exit-site infection associated with continuous ambulatory peritoneal dialysis(CAPD). However, some previous reports in the literature have suggested that IP administration of certain vancomycin may be associated with chemical peritonitis in CAPD patients. METHODS: Between 1 February 1994 and 1 February 1997, 35 consecutive CAPD patients requiring treatment with intraperitoneal vancomycin for either exit-site infection or peritonitis in the Yeungnam University Hospital were recruited retrospectively into the study. We compared retrospectively the incidence of chemical peritonitis after using two different preparations of vancomycin from different pharmaceutical companies, namely vancocin CP(R) and vancomycin(R). RESULTS: Thirty-three cases(all 26 cases given vancocin CP(R) and 7 out of the 9 cases given vancomycin(R)) showed improvement. None of them developed fever, abdominal pain or cloudy dialysate. Out of the 9 cases given IP vancomycin(R), two who currently did not have abdominal pain and cloudy dialysis effluent develolped these symptom and sign at 5 and 6 hours after administration of IP vancomycin. The chemical peritonitis may be secondary to prolonged contact of the peritoneal membrane with one or more of the impurities present in vancomycin preparation. CONCLUSION: In summary, it is necessary for the nephrologists to be aware of the possible chemical peritonitis which can be caused by the impurities of certain brand of vancomycin.
Abdominal Pain
;
Dialysis
;
Fever
;
Humans
;
Incidence
;
Membranes
;
Peritoneal Dialysis, Continuous Ambulatory*
;
Peritonitis*
;
Retrospective Studies
;
Vancomycin*
3.Maternal Psychosocial Factors that Affect Breastfeeding Adaptation and Immune Substances in Human Milk.
Eun Sook KIM ; Mi Jo JEONG ; Sue KIM ; Hyun A SHIN ; Hyang Kyu LEE ; Kayoung SHIN ; Jee Hee HAN
Korean Journal of Women Health Nursing 2014;20(1):14-28
PURPOSE: This study was to identify relationships of maternal psychosocial factors including mother's mood state, childcare stress, social support and sleep satisfaction with breastfeeding adaptation and immune substances in breast milk, especially secretory immunoglobulin A (sIgA) and transforming growth factor-beta 2 (TGF-beta2). METHODS: Data were collected from 84 mothers who delivered full-term infants by natural childbirth. Structured questionnaires and breast milk were collected at 2~4 days and 6 weeks postpartum. Data were analyzed using descriptive statistics, Pearson's correlation, multiple linear regression, and generalized estimating equation (GEE). RESULTS: Scores for the breastfeeding adaptation scale were significantly related with child care stress, mood state and social support. Mother's anger was positively correlated with the level of sIgA in colostrum (p<.01). Immune substances of breastmilk was significantly influenced by time for milk collection (p<.001) and the type of breastfeeding (sIgA, p<.001, TGF-beta2, p=.003). Regression analysis showed that breastfeeding adaptation could be explained 59.1% by the type of breastfeeding, childcare stress, the Profile of Mood States, emotional support and sleep quality (F=16.67, p<.001). CONCLUSION: The findings from this study provide important concepts of breastfeeding adaptation program and explanation of psychosocial factors by immune substances in breast milk. Future research, specially, bio-maker research on breast milk should focus on the ways to improve breastfeeding adaptation.
Adaptation, Psychological
;
Anger
;
Breast Feeding*
;
Child
;
Child Care
;
Colostrum
;
Female
;
Humans
;
Immunoglobulin A, Secretory
;
Immunologic Factors
;
Infant
;
Linear Models
;
Milk
;
Milk, Human*
;
Mothers
;
Natural Childbirth
;
Postpartum Period
;
Pregnancy
;
Psychology*
;
Surveys and Questionnaires
;
Transforming Growth Factor beta2
4.The Effect of Catheter Revision on Intractable Exit Site Infection in CAPD Patients.
Tae Woo KIM ; Jun Young DO ; Sung Hyun LEE ; Dong Un BAE ; Kyu Hyang JO ; Jong Won PARK ; Kyung Woo YOON
Korean Journal of Nephrology 2004;23(5):753-762
BACKGROUND: Continuous ambulatory peritoneal dialysis (CAPD) is an important method of renal replacement therapy in chronic renal failure, and reduction of dialysis-associated complication is essential to successful peritoneal dialysis. But catheter related infection is a major cause of catheter loss and transferring to hemodialysis. We use an unique catheter revision method for the treatment of intractable exit-site/tunnel infection in CAPD patients. METHODS: We reviewed 322 CAPD patients on the ESI/TI from May 1995 to January 2003 at Yeungnam University Hospital. Forty-four patients had exit-site infection more than one times. Prevalence of exit-site infection, kinds of causative micro- organism and results of catheter revision were analyzed retrospectively. RESULTS: Total follow-up was 5, 834 patient months. ESI occurred on 141 occasions in 44 patients out of 322 patients and cumulative incidence of ESI was 1 per 41.4 patient months. We started empiric antibiotic therapy with oral penicillinase- resistant penicillin and quinolones, thereafter adjusted antibiotics according to the results of culture and sensitivity. The most common organism responsible for ESI was Staphylococcus aureus (MSSA, 34.8%), followed by Pseudomonas aeruginosa (25.5%). Nineteen patients had to be treated with catheter revision to control intractable ESI/TI. With analysis of ten patients who showed relapsed ESI after catheter revision, 5 patients improved with antibiotic therapy and 3 patients improved with additional secondary revision, but remaining 2 patients showed removal of peritoneal catheter to treat combined peritonitis. CONCLUSION: Catheter revision technique can be regarded as an effective alternative method to treat intractable exit site/tunnel infection before removal of catheter in CAPD patients.
Anti-Bacterial Agents
;
Catheters*
;
Follow-Up Studies
;
Humans
;
Incidence
;
Kidney Failure, Chronic
;
Penicillins
;
Peritoneal Dialysis
;
Peritoneal Dialysis, Continuous Ambulatory*
;
Peritonitis
;
Prevalence
;
Pseudomonas aeruginosa
;
Quinolones
;
Renal Dialysis
;
Renal Replacement Therapy
;
Retrospective Studies
;
Staphylococcus aureus
5.The Effects of Catheter Revision and Mupirocin on Exit Site Infection/Peritonitis in CAPD Patients.
Jun Beom PARK ; Jung Mee KIM ; Jun Hyuk CHOI ; Kyu Hyang JO ; Hang Jae JUNG ; Yeung Jin KIM ; Jun Yeung DO ; Kyung Woo YOON
Yeungnam University Journal of Medicine 1999;16(2):347-356
BACKGROUND: Exit site/tunnel infection causes cosiderable morbidity and technique failure in CAPD patients. We presently use a unique revision method for the treatment of refractory ESI/TI in CAPD patients and mupirocin prophylaxis for high risk patients. MATERIALS AND METHODS: We reviewed 139 CAPD patients about the ESI/TI from October 1993 to February 1999 at Yeungnam University Hospital. At the beginning of the ESI, we usually started medications with rifampicin and ciprofloxacin and then changed the antibiotics according to the sensitivity test. If the ESI had persisted and there were T1 symptoms(purulent discharge, abscess lesion around exit site), we performed catheter revision(external cuff shaving, disinfection around tunnel and new exit site on opposit direction) with a combination of proper antibiotics. We applied local mupirocin ointment at the exit site three times per week to the 34 patients who had the risk of ESI starting from October 1998. RESULTS: The total follow-up was 2401 patient months(pt. mon). ESI occurred on 105 occasions in 36 out of 139 patients, and peritonitis occurred on 112 occasions in 67 out of 139 patients. The total number of incidences of ESI and peritonitis was 1 per 23.0 pt.mon and 0 per 21.6 pt.mon. The most common organism responsible for ESI was Staphylococcus aureus(26 of 54 isolated cases, 48%), followed by the Methicillin resistant S. auresu(MRSA) (13 cases, 24%). Seven patients(5: MRSA, 2: Pseudomonas) had to be treated with a revision to control infection. Three patients experienced ESI relapse after revision. One of them improved with antibiotics, while another needed a second revision and the remaining required catheter removal due to persistent MRSA infection with re-insertion at the same time. But, there was no more ESI in these 3 patients who were received management to relapse (The mean duration: 14.0 months). The rates of ESI were significantly reduced after using mupirocin than before(1 per 12.7 vs 34.0 pt.mon, p<0.01). CONCLUSION: In summary, revision technique can be regarded as an effective method for refractory ESI/T1 before catheter removal. Also local mupirocin ointment can play a significant role in the prevention of ESI.
Abscess
;
Anti-Bacterial Agents
;
Catheters*
;
Ciprofloxacin
;
Disinfection
;
Follow-Up Studies
;
Humans
;
Incidence
;
Methicillin Resistance
;
Methicillin-Resistant Staphylococcus aureus
;
Mupirocin*
;
Peritoneal Dialysis, Continuous Ambulatory*
;
Peritonitis
;
Recurrence
;
Rifampin
;
Staphylococcus
6.Empyema and Pericarditis by Salmonella Group D Complicating Malignant Thymoma with Pleural Metastasis: A case report.
Deog Gon CHO ; Min Seop JO ; Kyu Do CHO ; So Hyang SONG ; Chi Hong KIM ; Sun Hee LEE
The Korean Journal of Thoracic and Cardiovascular Surgery 2004;37(4):382-385
Non-typhoid salmonella infection frequently associated with bacteremia has rarely been reported in immunocompromized patients with malignant neoplasms, diabetes or extended use of corticosteroids. Especially, concomitant pleural empyema and pericarditis due to non-typhoid salmonella infection is extremely rare. Here, we report a case of concomitant empyema and pericarditis in malignant thymoma with pleural metastasis complicated by salmonella group D infection with brief review of literature.
Adrenal Cortex Hormones
;
Bacteremia
;
Empyema*
;
Empyema, Pleural
;
Humans
;
Neoplasm Metastasis*
;
Pericarditis*
;
Salmonella Infections
;
Salmonella*
;
Thymoma*
7.A Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin for Treatment in Patients with Previously Untreated Advanced Colorectal Cancer.
Sang Byung BAE ; Nam Su LEE ; Han Jo KIM ; Kyoung Ha KIM ; Hyun Jung KIM ; Chan Kyu KIM ; Kyu Taeg LEE ; Sung Kyu PARK ; Jong Ho WON ; Dae Sik HONG ; Hee Sook PARK
Cancer Research and Treatment 2006;38(2):72-77
PURPOSE: We prospectively conducted a non-randomized phase II trial to evaluate the efficacy and safety of combination irinotecan, leucovorin (LV) and 5-fluorouracil (FU) as a first-line regimen for treating patients with previously untreated advanced colorectal cancer (CRC). MATERIALS AND METHODS: Twenty-six previously untreated patients with advanced, recurrent or metastatic CRC were enrolled in this study. The patients received either irinotecan 180 mg/m2 on day 1 with LV bolus of 200 mg/m2 and FU bolus of 400 mg/m2, and this was followed by FU continuous infusion of 600 mg/m2 on day 1 and day 2 (the FOLFIRI regimen), or they were treated with LV bolus of 400 mg/m2 and FU bolus of 400 mg/m2 followed by FU continuous infusion of 2,400 mg/m2 for 46 hours (the simplified FOLFIRI regimen), and these treatments were repeated every 2 weeks until disease progression. RESULTS: The objective response rate was 23.1% (6/26) respectively, for both treatments. The median time to progression was 5.3 months (range: 0.4~19.9), and the overall survival was 11.2 months (range: 0.5~52.3). The prognostic factor for longer survival was the Eastern Cooperative Oncology Group (ECOG) performance status (PS). The non-hematological toxicities were similar for both treatment groups, with more frequent grade > or =3 neutropenia being noted for the simplified FOLFIRI regimen. CONCLUSION: The biweekly irinotecan based regimen was demonstrated to have a moderate antitumor activity with acceptable toxicity profiles, and the ECOG PS was the independent prognostic factor.
Colorectal Neoplasms*
;
Disease Progression
;
Fluorouracil*
;
Humans
;
Leucovorin*
;
Neutropenia
;
Prospective Studies
8.Surgical Treatment Guidelines for Patients with Differentiated Thyroid Cancer: The Korean Association of Thyroid and Endocrine Surgeons (KATES) Guidelines Taskforce.
Jin Woo PARK ; Ki Wook CHUNG ; Ji Sup YUN ; Hyungju KWON ; Hoon Yub KIM ; Kee Hyun NAM ; Kyoung Sik PARK ; Min Ho PARK ; Ja Sung BAE ; Hyun Jo YOUN ; Kyu Eun LEE ; Chi Young LIM ; Jin Hyang JUNG ; Jun Ho CHOE ; Lee Su KIM ; Su Jung LEE ; Jung Han YOON
Korean Journal of Endocrine Surgery 2017;17(1):1-18
No abstract available.
Humans
;
Surgeons*
;
Thyroid Gland*
;
Thyroid Neoplasms*
9.Primary Polymorphous Low-Grade Adenocarcinoma of Lung Treated by Sleeve Bronchial Resection: A Case Report.
Kyu Do CHO ; Ji Han JUNG ; Deog Gon CHO ; Min Seop JO ; Jinyoung YOO ; So Hyang SONG ; Byoung Yong SHIM ; Chi Hong KIM ; Hoon Kyo KIM
Journal of Korean Medical Science 2007;22(2):373-376
We report a surgical case of primary polymorphous low-grade adenocarcinoma (PLGA) of the minor salivary gland-type of the lung. A PLGA originating from the right upper lobar bronchial inlet was successfully treated by sleeve right upper lobectomy. PLGAs are thought to be indolent tumors that are preferentially localized to the palate, and they affect the minor salivary glands almost exclusively. Until now, two cases of distant metastases to the lung have been reported in the English literature. To the best of our knowledge, only one case of PLGA of minor salivary glandtype of the lung without evidence of a previous oropharyngeal primary tumor has been reported in the English literature. But the case was not a single lesion; it was bilateral tumors accompanied by tumors of the cervical lymph nodes. We report here the first case of a single primary PLGA of the minor salivary gland-type of the lung, which was successfully treated by sleeve bronchial resection of right upper lobe.
Treatment Outcome
;
Salivary Gland Neoplasms/pathology/*surgery
;
Lung Neoplasms/pathology/*secondary/*surgery
;
Humans
;
Female
;
Bronchi/*surgery
;
Aged
;
Adenocarcinoma/pathology/*secondary/*surgery
10.The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy.
Byoung Yong SHIM ; Chi Hong KIM ; So Hyang SONG ; Meyung Im AHN ; Eun Jung HONG ; Sung Whan KIM ; Suzy KIM ; Min Seop JO ; Deog Gon CHO ; Kyu Do CHO ; Jinyoung YOO ; Hoon Kyo KIM
Cancer Research and Treatment 2005;37(6):339-343
PURPOSE: When used in the second-line setting, single- agent chemotherapy has produced response rates of more than 10% or median survival times greater than 4 months. We studied the safety and efficacy of using second-line single docetaxel (75 mg/m2) for advanced NSCLC patients who were previously treated with platinum-based chemotherapy in Korea. MATERIALS AND METHODS: Thirty-three patients with advanced NSCLC received chemotherapy from May 2002 to January 2005. We retrospectively reviewed the charts of these patients. The patients received 75 mg/m2 of doxetaxel on day 1 and this was repeated at 3-week intervals. RESULTS: The median age was 63 years (range: 42~77 years); 16 patients had adenocarcinoma and 8 patients had squamous cell carcinoma. The median number of cycles was 4 (range: 1~7 cycles). Of the 33 patients, 6 patients had partial responses, 13 patients had stable disease and 14 patients had progressive disease. The response rate was 18.2%. The median overall survival was 11 months (range: 7~15 months), and the median progression free survival was 5 months (range: 3~7 months). The median response duration was 5 months (range: 4~9 months). A total of 137 cycles were evaluated for toxicity. We observed grade 3 or 4 neutropenia in 79 cycles (57.6%), grade 3 or 4 leukopenia in 46 cycles (33.6%), and grade 3 febrile neutropenia in 2 cycles (1.5%). The median nadir day was day 9 (range: day 5~19), and the median number of G-CSF injections was 2 (range: 0~6). The most common non-hematologic toxicities were myalgia/arthralgia and neurotoxicity, but any grade 3 or 4 non-hematologic toxicity was not observed. The major toxicity of this therapy was neutropenia. The absolute neutrophil count decreased relatively rapidly, but neutropenic fever or related infection was rare. There were no treatment-related deaths. CONCLUSION: These results revealed a satisfactory response rate (18.2%) with using docetaxel as the second- line chemotherapy for NSCLC. The second-line docetaxel was an active and well-tolerated regimen in patients with advanced NSCLC pretreated with platinum-based chemotherapy.
Adenocarcinoma
;
Carcinoma, Non-Small-Cell Lung*
;
Carcinoma, Squamous Cell
;
Disease-Free Survival
;
Drug Therapy*
;
Febrile Neutropenia
;
Fever
;
Granulocyte Colony-Stimulating Factor
;
Humans
;
Korea
;
Leukopenia
;
Neutropenia
;
Neutrophils
;
Retrospective Studies